Copyright © 2004 by the Johns Hopkins Bloomberg School of Public Health
ORIGINAL CONTRIBUTIONS |
Toenail Arsenic Content and Cutaneous Melanoma in Iowa
1 Division of Cancer Prevention, National Cancer Institute, Bethesda, MD.
2 Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA.
3 Department of Occupational and Environmental Health, College of Public Health, University of Iowa, Iowa City, IA.
4 Department of Civil and Environmental Engineering, University of Iowa, Iowa City, IA.
Cutaneous melanoma has the lowest survival rate of all forms of skin cancer. There has been little research investigating the link between arsenic and cutaneous melanoma, although arsenic has been associated with increased risk of nonmelanoma skin cancer. The authors performed a case-control study examining the association between cutaneous melanoma and environmental arsenic exposure among Iowans aged 40 years or older. Participants included 368 cutaneous melanoma cases and 373 colorectal cancer controls diagnosed in 1999 or 2000, frequency matched on gender and age. Participants completed a mailed survey and submitted toenail clippings for analysis of arsenic content by graphite furnace atomic absorption spectrophotometry. The authors found an increased risk of melanoma for participants with elevated toenail arsenic concentrations (odds ratio = 2.1, 95 percent confidence interval: 1.4, 3.3; p-trend = 0.001) and effect modification by prior skin cancer diagnosis (p-interaction = 0.03). The arsenic-melanoma findings in this study are not known to have been previously reported in observational epidemiologic studies involving incident cutaneous melanoma. Therefore, the findings warrant confirmation.
arsenic; case-control studies; melanoma; skin neoplasms
Abbreviations: Abbreviations: CI, confidence interval, OR, odds ratio
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. L. Meyskens Jr. and M. Berwick UV or Not UV: Metals Are The Answer Cancer Epidemiol. Biomarkers Prev., February 1, 2008; 17(2): 268 - 270. [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Vandenbroucke, E. v. Elm, D. G. Altman, P. C. Gotzsche, C. D. Mulrow, S. J. Pocock, C. Poole, J. J. Schlesselman, M. Egger, and for the STROBE initiative Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration Ann Intern Med, October 16, 2007; 147(8): W-163 - W-194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-F. Lin, J. Yang, and B. P. Rosen ArsD Residues Cys12, Cys13, and Cys18 Form an As(III)-binding Site Required for Arsenic Metallochaperone Activity J. Biol. Chem., June 8, 2007; 282(23): 16783 - 16791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-F. Lin, A. R. Walmsley, and B. P. Rosen An arsenic metallochaperone for an arsenic detoxification pump PNAS, October 17, 2006; 103(42): 15617 - 15622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Kile, E. A. Houseman, E. Rodrigues, T. J. Smith, Q. Quamruzzaman, M. Rahman, G. Mahiuddin, L. Su, and D. C. Christiani Toenail Arsenic Concentrations, GSTT1 Gene Polymorphisms, and Arsenic Exposure from Drinking Water Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2419 - 2426. [Abstract] [Full Text] [PDF]
|
|